Navigation Links
RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
Date:12/12/2008

y protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs, innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income o
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
2. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
3. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
4. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
5. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
6. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
7. New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
8. Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful
9. Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows
10. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
11. Soft Contact Lenses Do Not Lead to Myopic Creep in Children, Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese ... (API) released unaudited preliminary financial results for the ... Fiscal Year 2015 Ended September 30, 2014 Financial ... with $14.7 million in 1Q14 with gross margins ...
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... Inc. (Nasdaq: BCRX) today announced that it has delivered ... announced on September 21, 2009 from the U.S. Department ... of intravenous (i.v) peramivir for the treatment of critically ... BioCryst management intends to provide an update once the ...
... , CORAL GABLES, Fla., Sept. 30 Catalyst Pharmaceutical ... the Company will continue to develop CPP-109 (Catalyst,s version ... addiction. The Company,s decision was made after, and based ... its 186-patient Phase II clinical trial evaluating the use ...
Cached Medicine Technology:BioCryst Provides Update Regarding Peramivir for Influenza 2BioCryst Provides Update Regarding Peramivir for Influenza 3BioCryst Provides Update Regarding Peramivir for Influenza 4BioCryst Provides Update Regarding Peramivir for Influenza 5Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 2Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 3Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 4Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 5Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 6
(Date:12/25/2014)... (PRWEB) December 25, 2014 Parker & ... outstanding customer service and affordable quality regarding heating, cooling ... announces recognition in 2014 by the “Queen of Clean” ... has earned an impressive reputation over the years for ... a wide range of contractor services for both homeowners ...
(Date:12/24/2014)... Epigenetics finds applications in a large number of fields ... biology, and research for metabolic and genetic disorders. It ... used techniques for the discovery and development of cancer ... rapidly growing worldwide. In 2012, there were 14.1 million ... million people living with cancer (within five years of ...
(Date:12/24/2014)... December 24, 2014 Risperdal lawsuit ( ... mass tort litigation currently underway in Pennsylvania’s Philadelphia Court ... of December 24, 2014, court documents indicate that 1,183 ... of individuals who developed gynecomastia (male breast growth) and ... the Court indicates that this represents an increase of ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The ... that allege the blood thinner caused life-threatening episodes ... a leadership structure for the proceeding, Bernstein Liebhard ... 17th, the Court plans to select lawyers to ... also plans on appointing a Plaintiffs’ Steering Committee, ...
(Date:12/24/2014)... TX (PRWEB) December 25, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. Stivarga is a drug which is used ... drug is orally administered and is also prescribed to ... drug which is FDA approved is a multi-kinase inhibitor ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... is Leading Proponent for Single-Payer Healthcare ... Reforms - ,Medicare ... camera on the,fastest-growing union in America -- and the nation,s ... California Nurses,Association/National Nurses Organizing Committee,s fight for guaranteed,single-payer healthcare in ...
... odds of heart attack, death, study finds , , THURSDAY, May ... can hear when passing a stethoscope over a main artery ... attack and death from heart disease and stroke, a new ... (pronounced brew-ee) -- is caused by turbulent blood flow due ...
... 6, 2008) The American Society of Hematology (ASH) ... for its 2008 Minority Medical Student Award Program (MMSAP), ... in hematology research. Under the program, each award recipient ... a career development mentor, travel stipends to attend medical ...
... $0.18 In Line with Previously Announced ... Expectations, ... largest air medical transportation company in the,world, reported financial results for the ... flight volumes. For the quarter,revenue increased 45.0% to $118.1 million from $81.5 ...
... Corporation is launching a,third dental industry-focused online Tradeshow, ... is now open and available at, http://www.ddstechfair.com . ... bring dental professionals together with,colleagues and manufacturers at ... Tech Fair is designed to give the dental ...
... role in development of defective cells in type 2 diabetics ... an important gene during fetal development appears to increase vulnerability ... , Intrauterine growth retardation (IUGR), which causes low birth ... type 2 diabetes and other diseases when a child grows ...
Cached Medicine News:Health News:Bill Moyers' Journal to Feature California Nurses Association/National Nurses Organizing Committee in Friday, May 9th Episode 2Health News:Noise in Artery Could Warn of Heart Risk 2Health News:Minority medical students receive support to increase diversity in hematology 2Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 2Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 3Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 4Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 5Health News:Air Methods Reports 1Q2008 Results and 2Q2008 Update 6Health News:PennWell Announces DDS Tech Fair 2Health News:Fetal Gene May Contribute to Diabetes Risk 2
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
... is a fully adjustable, air-displacement pipette with ... the latest member of the Pipetman family, ... accuracy, and precision. We also added a ... our customers. Eight models cover the full ...
... Hamilton is precision, ergonomics, and ... hand fatigue with soft non-slip, contoured ... with smooth, light plunger spring action ... and sterilization without the need for ...
... first Sysmex hematology analyzer designed for a ... its small footprint, closed tube sampling, and ... of whole blood sample, you have a ... the emergency room, surgical suite, or small ...
Medicine Products: